跳到正文
原文
Medical Xpress·· 2026-10-13精选AI 评分79

TRIUMPH-2 三期试验显示 retatrutide 显著改善肥胖合并 2 型糖尿病患者的体重与代谢指标

Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds

AI 导读

Lilly 开发的 retatrutide 在 TRIUMPH-2 三期双盲随机对照试验中,使 1152 名合并肥胖与 2 型糖尿病的成年受试者在 80 周后最高剂量组平均减重 18.8%,远高于安慰剂组的 5.1%。该研究发表于 The Lancet,结果显示 retatrutide 在降低 HbA1c 及改善心血管风险指标方面优于安慰剂,主要不良反应为消化道症状。

推荐理由

原文呈现了Illumina的TRIUMPH-2试验结果,读者可据此对比三靶点机制与单双靶点药物在2型糖尿病减重上的差异。

正文 · 原文
Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds
Credit: Image generated by the editorial team using AI for illustrative purposes.

A recent Phase III clinical trial, TRIUMPH-2, evaluated the efficacy and safety of retatrutide, a triple receptor agonist and experimental once-weekly injection being developed to treat obesity and type 2 diabetes. What sets it apart from drugs such as semaglutide (Wegovy), which targets one hormone, and tirzepatide (Zepbound), which targets two, is its ability to activate three hormone receptors at once.

Developed by Eli Lilly, retatrutide mimics GLP-1, which lowers blood sugar and promotes fullness, and GIP, which enhances the body's insulin response and helps reduce body weight alongside GLP-1. It also activates glucagon receptors, adding a third mechanism that increases energy expenditure and metabolic activity, helping the body burn more energy.

After 80 weeks of once-weekly injections, 1,152 adults living with both obesity and type 2 diabetes saw major changes on the scale. Those on the highest dose lost an average of 18.8% of their body weight, roughly 20.7 kg (about 45.5 pounds), compared with 5.1% in the placebo group. The loss was even bigger for those who started with a BMI of 35 or higher, who lost an average of 21.9% of their body weight on the 12 mg dose.

The findings are published in The Lancet.

Overcoming the body's resistance

Weight loss isn't always about meeting existing beauty standards. It can be medically necessary, since weight gain is linked to many metabolic and cardiovascular conditions. Studies show that even a modest weight loss of 5–10% can lower both systolic and diastolic blood pressure and raise good cholesterol.

For people with type 2 diabetes, losing weight has historically been a tougher challenge than for those without the condition. The advent of glucagon-like peptide-1 receptor agonists, better known as GLP-1 agonists, has helped change that, making weight loss more achievable for people with obesity and type 2 diabetes.

Medicines such as semaglutide and tirzepatide improve weight and blood sugar, but they rarely achieve an average weight loss greater than 15% in people with type 2 diabetes. In previous trials of retatrutide, researchers observed up to 25% weight loss among participants.

The drug's third target—glucagon receptor agonism—alongside GLP-1 and GIP may explain its ability to overcome the body's resistance and unlock greater weight loss for people with diabetes.

The 80-week TRIUMPH-2 trial was designed to put once-weekly retatrutide to the test in adults living with both obesity and type 2 diabetes. Researchers wanted to find out whether it could push weight loss beyond previous limits while safely improving blood sugar control, overall cardiometabolic health and physical quality of life.

They designed a randomized, double-blind, placebo-controlled trial in which neither the participants nor medical staff knew who received retatrutide and who received a placebo. Participants were randomly assigned to receive retatrutide at 4 mg, 9 mg or 12 mg weekly, or a weekly placebo. To help the body adjust, retatrutide dosing started at 2 mg and increased every four weeks until participants reached their target dose.

Outcomes of triple-action treatment

After 80 weeks, participants taking retatrutide lost an average of 11.9%, 16.8% and 18.8% of their body weight as the dose increased, compared with 5.1% in the placebo group. At the highest dose, 12 mg, 75% of participants shed at least 10% of their body weight, while nearly one-third of participants lost 25% or more, a level of weight loss comparable with bariatric surgery.

The benefits extended beyond weight loss. Retatrutide reduced HbA1c, a marker of long-term blood sugar control, by 1.4–1.5 percentage points, compared with 0.45 percentage points with placebo. Participants saw improvements in several cardiovascular risk markers, as well as reductions in waist circumference, systolic blood pressure and triglyceride levels.

Triple-action drug retatrutide delivers major weight loss for people with diabetes, finds new randomised phase-3 trial
Bodyweight and bodyweight reduction thresholds for the overall population and participants with BMI 35 kg/m2 or higher. Credit: The Lancet (2026). DOI: 10.1016/s0140-6736(26)01861-1

The side effects seen in participants were mostly digestive, with diarrhea in up to 34% of participants, nausea in up to 28% and vomiting in up to 16%. Adverse events led 8–12% of participants in the two higher-dose groups to discontinue treatment, compared with 5% in the placebo group.

Based on the trial results, retatrutide looks promising for treating obesity in people with type 2 diabetes, but more research is needed to find out whether those benefits extend to other obesity-related complications.

Written for you by our author Sanjukta Mondal, edited by Sadie Harley, and fact-checked and reviewed by Robert Egan—this article is the result of careful human work. We rely on readers like you to keep independent science journalism alive. If this reporting matters to you, please consider a donation (especially monthly). You'll get an ad-free account as a thank-you.

Publication details

Virginia Bellido et al., Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial, The Lancet (2026). DOI: 10.1016/s0140-6736(26)01861-1

Journal information: The Lancet

Who's behind this story?

Sanjukta Mondal

Sanjukta Mondal

Master's in Chemistry. Freelance science journalist and communicator. Published in Chemistry World, BioSpace, and The Hindu. Full profile →

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

© 2026 Science X Network

Citation: Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds (2026, October 13) retrieved 13 October 2026 from https://medicalxpress.com/news/2026-10-triple-action-drug-retatrutide-major.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com